Naltrexone Dose Titration Protocol Over 7 Days
For opioid dependence treatment, naltrexone should be initiated at 25 mg on the first day, then increased to 50 mg daily thereafter if no withdrawal signs occur. 1
Initial Requirements Before Starting Naltrexone
- Ensure patient is completely detoxified from opioids with a drug-free period of 7-10 days prior to first dose 2
- Verify opioid-free status through either:
Naloxone Challenge Test Protocol
Intravenous method:
- Inject 0.2 mg naloxone and observe for 30 seconds for withdrawal signs
- If no withdrawal signs appear, inject 0.6 mg naloxone and observe for 20 additional minutes 1
Subcutaneous method:
- Administer 0.8 mg naloxone and observe for 20 minutes for withdrawal signs 1
7-Day Naltrexone Titration Schedule
- Day 1: Start with 25 mg oral naltrexone (half the standard dose) 1, 2
- Day 2-7: If no withdrawal signs occur, increase to the standard dose of 50 mg daily 1
Monitoring During Titration
Monitor for signs of opioid withdrawal which may include:
- Nausea, vomiting, dysphoria, yawning, sweating
- Tearing, rhinorrhea, stuffy nose, craving for opioids
- Abdominal cramps, sense of fear, skin erythema
- Anxiety, irritability, muscle aches or cramps 1
Perform liver enzyme tests before and during treatment 2
Special Considerations
Do not administer naltrexone to:
For patients requiring supervised administration, alternative dosing schedules may be considered:
- 50 mg every weekday with 100 mg on Saturday
- 100 mg every other day
- 150 mg every third day 1
Important Cautions
- Higher risk of hepatocellular injury may occur with single doses above 50 mg 1
- Naltrexone should be considered only one component of a comprehensive treatment program 1, 3
- Patients most likely to benefit from naltrexone therapy are those who are:
- Employed, married, stabilized on low-dose methadone prior to detoxification
- Highly motivated to maintain a non-opioid treatment regimen 3
This protocol provides a safe and effective method for initiating naltrexone therapy while minimizing the risk of precipitating withdrawal symptoms in patients transitioning from opioid dependence to abstinence.